Howard Kaufman

Howard Kaufman led the OPTiM phase III trial that established talimogene laherparepvec (T-VEC) as the first FDA-approved oncolytic virus therapy for melanoma. His research has explored mechanisms by which T-VEC induces local and distant immune responses. He has also investigated combining T-VEC with pembrolizumab and other checkpoint inhibitors to augment systemic anti-tumor immunity.